Despite this observation, TCGA data available at UALCAN showed that high levels of PSMD3 mRNA expression correlated with a significant reduction of OS when all AML subtypes were considered (p = 0.0029, Figure 1E), and this was especially true for AML patients with FLT3 mutations (p = 0.0015, Figure 1F). This evidence concerns the gene FLT3 and acute myeloid leukemia.